While we do not disregard that some of luteolin’s anti-cancer effects may be through alternate signaling pathways, we do posit that its activity as a RSK inhibitor could have a particularly significant effect in the context of TNBC given that RSK signaling is critical to the survival of this breast cancer subtype [10]. This evidence concerns the gene RPS6KA1 and cancer.